Table 2.
Ex vivo expansion conditions for adoptive immunotherapy using ex vivo activated Vγ9Vδ2 T cells.
| Reference | Number of Patients | Disease | Cell Source | Culture condition | ||||
|---|---|---|---|---|---|---|---|---|
| IL-2 | Stimulant (Concentration) | Serum | Culture days | |||||
| Kobayashi et al., 2007 Cancer Immunol. Immunother. [22] | 7 | RCC | PB | 100 U/mL | 2M3B1-PP | 100 μM | 2% Auto serum | 14 days |
| Bennouna et al., 2008 Cancer Immunol. Immunother. [21] | 10 | RCC | Leukapheresis | 328 U/mL: d1, 984 U/mL: d4–14 | BrHPP | 3 μM | 9% FCS | 14 days |
| Kobayashi et al., 2011 Cancer Immunol. Immunother. [23] | 11 | RCC | Leukapheresis (1 leukapheresis for 2 treatments) | 100 U/mL | 2M3B1-PP | 100 μM | 2% Auto serum | 11 days |
| Nicol et al., 2011 Br. J. Cancer [24] | 18 | Melanoma: 4, Ovarian cancer: 1, Colon cancer: 1 | Luekapheresis 1 leukapheresis for 8 treatments | 700 IU/mL, d0; 350 IU/mL, every 2–3 days | Zol | 1 μM | 10% AB serum | 7–14 days |
| Melanoma: 3 | ||||||||
| Adenocarcinoma: 1 | ||||||||
| Cholangiocarcinoma: 1 | ||||||||
| Ovarian carcinoma: 1 | ||||||||
| Colon cancer: 2 | ||||||||
| Duodenal cancer: 1 | ||||||||
| Breast cancer: 2, Cervical cancer: 1 | ||||||||
| Nakajima et al., 2010 Eur. J. Cardiothorac. Surg. [26] | 10 | Non-small-cell lung cancer | Peripheral blood 70 mL | 1000 U/mL | Zol | 5 μM | 10% Auto serum | 14 days |
| Abe et al., 2009 Exp. Hematol. [25] | 6 | Multiple myeloma | Peripheral blood | 1000 U/mL | Zol | 5 μM | Auto serum | 14 days |
| Wada et al., 2014 Cancer Med. [27] | 7 | Gastric cancer | Leukapheresis | 1000 U/mL | Zol | 5 μM | Auto serum | 14 days |